Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.67 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.61 |
| ▸ | MAOB | P27338 | 5/20 | 0.60 |
| ▸ | MAOA | P21397 | 4/20 | 0.60 |
| ▸ | KRAS | P01116 | 1/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7188944 | 1.00 | MEN1 (0.67) | MEN1MAPTMAPK1KMT2AUSP2 | |
| SCHEMBL7587229 | 0.86 | TUBB1 (0.62) | MEN1MAPTMAPK1KMT2AUSP2 | |
| SCHEMBL7613337 | 0.86 | TUBB1 (0.62) | MEN1MAPTMAPK1KMT2AUSP2 | |
| SCHEMBL7198238 | 0.85 | TUBB1 (0.65) | MEN1MAPTMAPK1KMT2AUSP2 | |
| SCHEMBL7198237 | 0.85 | TUBB1 (0.65) | MEN1MAPTMAPK1KMT2AUSP2 | |
| SCHEMBL15304531 | 0.85 | TUBB1 (0.71) | MEN1MAPTMAPK1KMT2ATUBB1 | |
| SCHEMBL10824463 | 0.85 | TUBB1 (0.76) | MEN1MAPTMAPK1KMT2ATUBB1 | |
| SCHEMBL10824465 | 0.85 | TUBB1 (0.76) | MEN1MAPTMAPK1KMT2ATUBB1 | |
| SCHEMBL18226864 | 0.85 | TUBB1 (0.57) | MEN1MAPTMAPK1KMT2AUSP2 | |
| SCHEMBL18226863 | 0.85 | TUBB1 (0.57) | MEN1MAPTMAPK1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020143064-A1 | Novel use of compounds of the chalcones class | AVENTIS PHARMA S.A. (FR) | 2002-10-03 | — | — | US | claimed |
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | STATENS SERUM INSTITUTE (DK) | 2003-04-03 | — | — | US | disclosed |
| US-20020143064-A1 | Novel use of compounds of the chalcones class | AVENTIS PHARMA S.A. (FR) | 2002-10-03 | — | — | US | disclosed |
| EP-0996432-A2 | BIOLOGICALLY ACTIVE 1,3-BIS-AROMATIC-PROP-2-EN-1-ONES, 1,3-BIS-AROMATIC-PROPAN-1-ONES, AND 1,3-BIS-AROMATIC-PROP-2-YN-1-ONES | STATENS SERUMINSTITUT (DK) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999000114-A2 | BIOLOGICALLY ACTIVE 1,3-BIS-AROMATIC-PROP-2-EN-1-ONES, 1,3-BIS-AROMATIC-PROPAN-1-ONES, AND 1,3-BIS-AROMATIC-PROP-2-YN-1-ONES | STATENS SERUM INSTITUT (DK) | 1999-01-07 | — | — | WO | disclosed |
| EP-0288794-B1 | Controlling the growth of tumor tissue with chalcone derivatives | MERRELL DOW PHARMA (US) | 1994-06-08 | — | — | EP | disclosed |
| EP-0286083-B1 | METHOD OF TREATING MULTIPLE SCLEROSIS WITH CHALCONE DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-08-04 | — | — | EP | disclosed |
| EP-0287901-B1 | METHODS FOR TREATING GOUT WITH CHALCONE DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-08-01 | — | — | EP | disclosed |
| US-4904697-A | Controlling the growth of certain tumor tissue with chalcone derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-02-27 | — | — | US | disclosed |
| US-4863968-A | Methods of treating gout with chalcone derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-05 | — | — | US | disclosed |
| US-4753965-A | INHIBITING DESTRUCTION OF MYELIN SHEATH; ANTIMITOTIC | MERRELL DOW PHARMACEUTICALS, INC. (US) | 1988-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143064-A1 | Novel use of compounds of the chalcones class | NR2E1, FLT1, KDR | MEN1 1826/4885MAPT 4830/4885MAPK1 1092/4885 |
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | AKR1C3, AKR1C1, AKR1A1 | MEN1 3878/4885MAPT 3817/4885MAPK1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.